Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir ± Ribavirin in Treatment-Naive Genotype 1 HCV
NCT01851330Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- May 2013
- Primary completion
- Dec 2013
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 3 trial of Harvoni in hepatitis C (HCV), sponsored by Gilead Sciences. Started May 2013; status: completed.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01851330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01851330.